In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Neuronetics (STIM), with a price target of $21.00. The company’s shares closed last Tuesday at $14.50.
According to TipRanks.com, Thibault is a top 100 analyst with an average return of 102.8% and a 72.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Irhythm Technologies.
Currently, the analyst consensus on Neuronetics is a Strong Buy with an average price target of $22.25, implying a 69.1% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.43 and a one-year low of $1.25. Currently, Neuronetics has an average volume of 449.5K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STIM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
